Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/cancerbiology.4.047
Network-based poly-pharmacological study sheds light on effective active constituents in Compound Kushen Injection preparations against lung cancer
Qian Cai1, Hui-Heng Lin2,*
- 1Center for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK
- 2Microbiology Society, UK
Corresponding Author
Hui-Heng Lin, molgen.v@gmail.com
Received Date: October 06, 2022
Accepted Date: December 19, 2022
Cai Q, Lin HH. Network-based poly-pharmacological study sheds light on effective active constituents in Compound Kushen Injection preparations against lung cancer. J Cancer Biol. 2023;4(1):1-2.
Copyright: © 2023 Cai Q, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Traditional Chinese Medicine (TCM) has been found to be effective in treating various diseases. However, the over-complicated compositions of TCM preparations precludes the study of their therapeutic mechanisms. Taking Liang et al. (2021)’s work as an example, this study aimed to discuss how complex network model-based systems biology or network pharmacology study approaches enabled the identification the active and effective ingredients of Compound Kushen Injection preparations in treating lung cancer.
Recommended Articles
The value of EGFR in individualized treatment for brain metastases in non-small cell lung cancer
The epidermal growth factor receptor (EGFR) is a member of the ErbB family. It is involved in biological processes such as cell proliferation, angiogenesis, inhibition of apoptosis, adhesion, metastasis, and is associated with the progression of lung cancer [1-3].
Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine
Lung cancer is the leading cause of cancer death among both men and women in the United States. Because lung cancer is genetically heterogeneous, tailored therapy alone or in combination with chemotherapy would increase patient overall survival as compared with the one-size-fits-all chemotherapy. TP53-mutant lung cancer accounts for more than half of all lung cancer cases and is oftentimes more aggressive and resistant to chemotherapy. Directly targeting mutant p53 has not yet been successful, so identification of novel therapy targets and biomarkers in the TP53-mutant lung cancer is urgently needed to increase the overall survival in this subgroup.
Changing the landscape of non-small cell lung cancer disparities
In the United States, lung and bronchus cancers are the second most common types of cancer and are responsible for the largest number of deaths from cancer, with African Americans suffering disproportionately from lung and bronchus cancers. This disparity likely results from a complex interplay among social, psycho-social, lifestyle, environmental, health system, and biological determinants of health.
Network-based poly-pharmacological study sheds light on effective active constituents in Compound Kushen Injection preparations against lung cancer
Traditional Chinese Medicine (TCM), the world’s oldest known herbal medicine, has long been used in several Asian countries. Emerging evidence has demonstrated their effectiveness and safety in the treatment of various diseases, ranging from mild flu to severe cancers. A great number of patients have benefited by receiving TCM therapies. However, due to the complex chemical compositions of TCM, which could produce highly complex compound-protein binding interactions, the molecular mechanisms underlying the pharmacological actions of TCM still remain poorly understood. Specifically, it is difficult to identify and isolate the effective constituents from the mixture of many compounds, even the therapeutic targets are known.